Objective To demonstrate the efficacy, tolerability, and safety of domestic Acarbose tablet compared with Glucobay (Acarbose tablet produced by Bayer company) in patients with type 2 diabetic patients. Method A multicenter randomized controlled parallel-group comparison study was conducted. 177 Chinese type 2 diabetic patients were recruited from 4 clinical centers. The patients were divided randomly into domestic Acarbose tablet (A group) or Glucoby (B group) treatment group. The trial consisted of a 2-4 weeks equilibrated period followed by an 8 week course of treatment. Results 165 patients have finished the trial (81 in A group and 84 in B group). After 4 weeks of treatment, the mean of fasting blood glucose (FBG) in A and B group were reduced 1.61 and 2.08 mmol/L respectively, and mean of postprandial blood glucose (PBG) lowered 5.06 and 5.09mmol/L respectively. After 8 weeks of treatment, the mean of FBG were reduced 1.95 and 2.62mmol/L respectively, and mean of PBG lowered 4.88 and 5.98 mmol/L, respectively, and mean of HbA1c were lowered 1.13% and 1.20% respectively in A and B group. The differences in reduction of FBG, PBG, and HbA1c between A and B group were no statistic significance. The serum triglyceride levels and BMI were decreased significantly in both A, B groups. 3 patients who drinking wine during trial on A group had asymptomatic elevations in serum transaminases that normalized in 2 weeks after stopped drinking and Acarbose withdrawal. Flatulence was the most common side effect. Conclusions In this multicenter study, domestic Acarbose tablet 50 mg t.i.d. was an effective, safe, and generally well-tolerated therapy as similar as Glucobay in type 2 diabetic patients.
【摘要】 目的 观察单用二甲双胍与二甲双胍联合阿卡波糖对2型糖尿病（type 2 diabetes mellitus，T2DM）降糖作用的临床疗效。 方法 对2010年1—10月就诊有典型易饥多食的T2DM患者45例，随机分为二甲双胍组20例和二甲双胍联合阿卡波糖25例，疗程12周。 结果 二甲双胍组与二甲双胍联合阿卡波糖组治疗后对患者的饥饿感和食量改善差异有统计学意义（Plt;0.05），空腹及餐后血糖差异（Plt;0.01）、空腹血糖达标比例差异（Plt;0.01）、餐后血糖达标比例差异（Plt;0.05）均有统计学意义。 结论 二甲双胍联合阿卡波糖能显著改善T2DM患者的食欲及食量，从而明显降低空腹及餐后血糖。【Abstract】 Objective To observe and compare the clinical affects and curative effects between using metformin and metformin plus acarbose in the treatment of type 2 diabetes mellitus (T2DM). Methods From January to October 2010, 45 T2DM patients with common symptoms of easy-starving and overeating were randomized into two groups and treated for 12 weeks with either metformin (n=20) or metformin plus acarbose (n=25). Results After the treatment, significant differences were found between the two groups in the improvement on patients’ sense of starving and quantity of eating (Plt;0.05), fasting and postprandial blood glucose (Plt;0.01), up-to-standard rate of fasting blood glucose (Plt;0.01), and up-to-standard rate of postprandial blood glucose (Plt;0.05). Conclusion The combination of metformin and acarbose can substantially improve the appetite and quantity of eating for patients with T2DM, hence significant reductions of fasting and postprandial blood glucose level can be feasibly achieved.
目的:观察甘精胰岛素、阿卡波糖与盐酸贝那普利联合治疗2型糖尿病早期肾病的临床疗效。方法:将62例2型糖尿病合并糖尿病肾病III期患者用甘精胰岛素作为基础量使空腹血糖达标,三餐时联合阿卡波糖口服控制餐后血糖,辅以盐酸贝那普利治疗,观察治疗前后血糖、血压及尿白蛋白/肌酐的变化。结果:经甘精胰岛素、阿卡波糖治疗后空腹和餐后2 h血糖明显下降,联合盐酸贝那普利治疗可改善胰岛素抵抗,并使UAER明显下降。结论:甘精胰岛素作为基础量、联合阿卡波糖控制血糖,辅以盐酸贝那普利口服是治疗2型糖尿病合并早期糖尿病肾病的方法之一,疗效肯定,无低血糖发生。
摘要:目的: 观察瑞格列奈、阿卡波糖联合治疗老年性2型糖尿病患者的临床疗效及安全性。 方法 :观察58例2型糖尿病患者服用瑞格列奈及阿卡波糖,疗程12周,监测治疗前后空腹及餐后2 h血糖(FBG、PBG)、糖化血红蛋白(HbAlc)、肝功、肾功。 结果 :FBG、PBG及HbAlc较治疗前显著下降(Plt;005),尤其是餐后血糖更为明显(Plt;001)。无一例肝肾功能损害,也无严重低血糖及其它严重不良反应发生。 结论 :瑞格列奈联合阿卡波糖治疗2型糖尿病降糖作用确切,而且安全性、耐受性良好。Abstract: Objective: To observe the clinical efficacy and safety of combined treatment of repaglinide and acarbose in aged patients with diabetes type 2 Methods : After oral administration of repaglinide and acarbose for 12 weeks, 58 patients with type 2 diabetes were observed. The concentrations of fasting blood glucose (FBG), 2 h postprandial blood glucose (PBG), glycosylated hemoglobin (HbAlc), liver and kidney functions were monitored before and after treatment. Results : The levels of FBG, PBG and HbAlc were significantly decreased compared with pretreatment (Plt;005), especially PBG (Plt;001). No case of liver and kidney dysfunction was found, without serious hypoglycemia and other serious adverse events as well. Conclusion : Repaglinide and acarbose have the precise function in the treatment of type 2 diabetes, with good security and good tolerance.